COMP <GO>
IQV vs JNJ // 10Y YIELD & FRED MACRO BETA
IQVIA Holdings Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IQV 2
— JNJ 12
▲ 10Y YIELD & FRED MACRO BETA LEADER: IQV
LAST: $267.33 (-2.81%) • MKT CAP: $45.33B
macro-sensitivity
1.16
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IQV VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IQV | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 25.50% | -16.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.4x | 18.5x | +1.90 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.24% | 2.97% | +1.27 | IQV | /fcf-yield <GO> |
| Operating Margin | 13.40% | 34.70% | -21.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 8.30% | 28.50% | -20.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.90% | 6.00% | -0.10 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 5.59 | -3.37 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.20% | +0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 60.4 | -11.35 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.16 | 1.08 | +0.08 | IQV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 23.0x | +8.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.33B | $662.49B | -$617.16B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IQV REV | JNJ REV | IQV GROSS % | JNJ GROSS % | IQV FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.31B | $94.19B | 44.0% | 67.9% | $1.92B | $19.70B |
| FY 2024 | $15.40B | $88.82B | 44.0% | 69.1% | $2.02B | $19.84B |
| FY 2023 | $14.98B | $85.16B | 44.0% | 44.0% | $1.47B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IQV // BETA 1.16
JNJ // BETA 1.08